Key result
Pre-existing hypertension before non-valvular AF onset was associated with more cardiovascular events compared to no hypertension (10.3 vs 4.4 per 1000 patient-years; P<.001).
Why the study?
The impact of pre-existing hypertension and blood pressure control status before the onset of AF on prognosis after AF onset had not been clarified.
Does pre-existing hypertension and its control status before NVAF onset impact the incidence of cardiovascular events in patients with new-onset NVAF?
Cohort (n=7,885)
Does pre-existing hypertension and its control status before NVAF onset impact the incidence of cardiovascular events in patients with new-onset NVAF?
Pre-existing hypertension and poor blood pressure control prior to the onset of non-valvular atrial fibrillation are associated with a significantly higher risk of subsequent cardiovascular events.
Pre-existing hypertension may flag higher-risk new-onset NVAF patients for closer monitoring; leaves open whether prior BP control modifies outcomes.
Hypertension is an important risk factor for non-valvular atrial fibrillation (NVAF) and its prognosis. However, there is no study to clarify the impact of pre-existing hypertension and BP control status before the onset of AF on the prognosis after the onset of AF. This retrospective real-world cohort analysis used data from the Japan Medical Data Center Co., Ltd database. The presence of NVAF and hypertension, plus the occurrence of adverse events, was based on ICD-10 codes in the database. The primary composite AF-related cardiovascular event end point included ischemic stroke, hemorrhagic stroke, and acute myocardial infarction. Of the 21 523 patients identified as having new-onset NVAF between January 2005 and June 2016, 7885 had blood pressure (BP) data before the onset of NVAF available and were included in the analysis (4001 with pre-existing hypertension and 3884 without pre-existing hypertension). The rate of primary composite end point events was 10.3 and 4.4 per 1000 patient-years in patients with and without hypertension, respectively (P < .001). In addition, lower systolic BP (<120 mm Hg) before the onset of NVAF was associated with a lower incidence of cardiovascular events after the development of NVAF (P < .001). This highlights the importance of earlier and tighter 24-hour BP control before the onset of NVAF in patients with hypertension, not only for reducing the occurrence of new-onset of NVAF, but also for reducing both hemorrhagic and ischemic cardiovascular events after the onset of NVAF.
No takes yet. Share an insight, caveat, or question.
Kario et al. (2019) conducted a cohort in Non-valvular atrial fibrillation (n=7,885). Pre-existing hypertension vs. No pre-existing hypertension was evaluated on Composite AF-related cardiovascular event (ischemic stroke, hemorrhagic stroke, and acute myocardial infarction) (p=<.001). Pre-existing hypertension before non-valvular AF onset was associated with more cardiovascular events compared to no hypertension (10.3 vs 4.4 per 1000 patient-years; P<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: